Filter
Period
Filter by
recent search
Showing: 1 – 05 of 118 Regulated Information
–
14 December 2022
14 December 2022
LinkedIn
Facebook
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation (heterotopic ossification) in people…
–
09 December 2022
09 December 2022
LinkedIn
Voting rights on 30 November 2022
This article or press release has no online content. Please download the associated documents for more information.
–
10 November 2022
10 November 2022
LinkedIn
Voting rights on 31 October 2022
This article or press release has no online content. Please download the associated documents for more information.
–
10 October 2022
10 October 2022
LinkedIn
Voting rights on 30 September 2022
This article or press release has no online content. Please download the associated documents for more information.
–
09 September 2022
09 September 2022
LinkedIn
Voting rights on 31 August 2022
This article or press release has no online content. Please download the associated documents for more information.